Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848689 · ClinicalTrials.gov registry record
FQ Restriction for the Prevention of CDI
A clinical trial, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- 5,871
- Enrollment target
NCT03848689: Completed study, sponsored by University of Wisconsin, Madison.
NCT03848689 is a clinical trial that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 5,871 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03848689 has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- 5,871 participants
- Enrollment target
Study Summary
This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs). The investigators will model a successful FQ PPA strategy in several Wisconsin ICUs and compare whether the intervention has improved outcomes in reducing CDIs. An additional goal of the study is to evaluate environmental and work system factors using systems engineering models in order to determine the most successful way to implement these new strategies.
Primary Outcome
Effectiveness of fluoroquinolone (FQ) Pre-prescription Authorization (PPA) intervention to reduce HO-CDI with ICU-onset will be assessed by comparing changes in incidence over pre- and post-intervention periods.
Interventions
- OTHER Control
- OTHER fluoroquinolone preprescription authorization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,871 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2024-05-31 |
What the finished NCT03848689 record still lists
NCT03848689 is an observational study that tracks outcomes without assigning an intervention. Its 5,871 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03848689 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03848689 about?
NCT03848689 is a clinical study titled "FQ Restriction for the Prevention of CDI". This study evaluates the effectiveness of a new intervention, fluoroquinolone (FQ) Preprescription Authorization (PPA) strategy, to reduce and prevent Clostridium difficile infection (CDI) in hospital intensive care units (ICUs). The investigators will model a successful FQ PPA strategy in several W...
What is the current status of trial NCT03848689?
This trial is currently completed. The enrollment target is 5,871 participants. The study started on 2019-05-01. Estimated completion is 2024-05-31.
What interventions are being tested in trial NCT03848689?
The interventions under investigation include: Control (OTHER), fluoroquinolone preprescription authorization (OTHER).
Who is sponsoring clinical trial NCT03848689?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03959085 · 5,951 participants · Phase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- NCT06192511 · 5,980 participants · NA
Implementing a Novel Consent Process for Biospecimen Research After Newborn Screening
- NCT00005095 · 6,000 participants
Specimen and Data Study for Ovarian Cancer Early Detection and Prevention
- NCT00280202 · 6,000 participants
Detection of Genetic Markers of Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI